Author + information
- Received July 15, 1993
- Revision received October 2, 1993
- Accepted October 15, 1993
- Published online March 1, 1994.
- David M. Kaye, MBBS, FRACPa,∗,1,
- Gavin W. Lambert, BSca,1,
- Jeffrey Lefkovits, MBBSa,
- Margaret Morris, PhD∗,
- Garry Jennings, MD, FRACPa and
- Murray D. Esler, MBBS, PhD, FRACPa
- ↵∗Address for correspondence: Dr. David M. Kaye, Alfred and Baker Medical Unit, Baker Medical Research Institute, Commercial Road, Prahran, Victoria 3181, Australia.
Objectives. The aim of this study was to characterize cardiac sympathetic nervous function in patients with severe heart failure and to investigate the influence of the cause of heart failure, hemodynamic variables and central nervous system catecholamine release on cardiac sympathetic tone.
Background. Although heart failure is generally accompanied by sympathoexcitation, the integrity of cardiac sympathetic nerve function in heart failure remains controversial, particularly in relation to nerve firing activity and to the capacity of sympathetic nerves to recapture norepinephrine. Additionally, the location of the afferent and central neural pathways implicated in heart failure-induced sympathoexcitation remains unclear.
Methods. Radiotracer techniques were applied in 41 patients with severe heart failure and 15 healthy control subjects to study the biochemical aspects of whole body and cardiac sympathetic activity. Hemodynamic indexes of cardiac performance were measured in the heart failure group, and their association with sympathetic activity was studied. Jugular venous catechol spillover was measured to study the central noradrenergic control of sympathetic outflow.
Results. Sympathoexcitation was evident in the heart failure group, reflected by a 62% increase (p < 0.001) in total body and a 277% increase (p < 0.001) in cardiac norepinephrine spillover rates. These changes were accompanied by significant increases in the cardiac spillover of the norepinephrine precursor dihydroxyphenylalanine, the sympathetic cotransmitter neuropeptide Y and the extraneuronal metabolite 3-methoxy-4-hydroxyphenylglycol. The level of cardiac sympathetic activity was significantly correlated (r = 0.59, p < 0.001) with the mean pulmonary artery pressure. An increase in the spillover of dihydroxyphenylalanine and 3-methoxy-4-hydroxyphenylglycol from the brain was present, suggesting activation of central noradrenergic neurons.
Conclusions. Cardiac sympathetic activation is present in severe heart failure, bearing a close relation with pulmonary artery pressures, independent of heart failure etiology. Activation of noradrenergic neurons in the brain is also present and may be the underlying central nervous mechanism of the sympathoexcitation observed in heart failure.
↵1 Drs. Kaye and Lambert are the recipients of Postgraduate Medical Research Scholarships from the National Health and Medical Research Council of Australia.
☆ This study was supported by an Institute Grant to the Baker Medical Research Institute from the National Health and Medical Research Council of Australia.
- Received July 15, 1993.
- Revision received October 2, 1993.
- Accepted October 15, 1993.